Galectin 9 Levels as a Potential Predictor of Intact HIV Reservoir Decay
The Journal of Infectious Diseases · 2025
DOI: 10.1093/infdis/jiae426 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift The Journal of Infectious Diseases, 2025. Verfasst von Sergio Serrano-Villar und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of HIV, Infectious Diseases, and Global Medicine, Department of Medicine, Zuckerberg San Francisco General Hospital, and University of Calif…. Hauptthemen laut MEDLINE: HIV Infections, Galectins, HIV-1. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, University of California San Francisco, NIH HHS.
Abstract (Originalsprache)
Background
During antiretroviral therapy (ART), the HIV reservoir shows variability, with cells carrying intact genomes decaying faster than those with defective genomes, particularly in the first years. The host factors influencing this decay remain unclear.
Methods
Observational study of 74 PWH on ART, 70 (94.6%) of whom were male. Intact proviruses were measured using the intact proviral DNA assay, and 32 inflammatory cytokines were quantified using Luminex immunoassay. Linear spline models assessed the impact of baseline cytokine levels and their trajectories on intact HIV kinetics over seven years.
Results
Baseline Gal-9 was the strongest predictor, with lower levels predicting faster decay. A 10-fold decrease in baseline Gal-9 correlated with a 45% (95% CI, 14%–84%) greater annual decay of intact HIV genomes. Higher baseline interferon-inducible T-cell α chemoattractant (ITAC), interleukin 17 (IL-17), and macrophage inflammatory protein 1α (MIP-1α) levels also predicted faster decay. Longitudinal increases in MIP-3α and decreases in IL-6 were linked to a 9.5% and 10% faster decay, respectively.
Conclusions
The association between lower baseline Gal-9 and faster intact HIV decay suggests targeting Gal-9 could enhance reservoir reduction. The involvement of MIP-3α and IL-6 highlights a broader cytokine regulatory network, suggesting potential multi-targeted interventions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of HIV, Infectious Diseases, and Global Medicine, Department of Medicine, Zuckerberg San Francisco General Hospital, and University of California San Francisco.
- Department of Infectious Diseases, Hospital Universitario Ramón y Cajal, and IRICYS.
- CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain.
- Vitalant Research Institute and University of California San Francisco.
- Department of Epidemiology and Biostatistics, University of California San Francisco.
- Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington.
ORCID-Profile: Sergio Serrano-Villar
Förderung
- NIAID NIH HHS
- University of California San Francisco
- NIH HHS
- I4C Collaboratory
- Instituto de Salud Carlos III
- Beat-HIV Collaboratory
- amfAR Institute
- DARE Collaboratory
Zitieren
APA
Serrano-Villar, S., Gala, A., Bacchetti, P., Hoh, R., di Germanio, C., Cohn, L. B., Henrich, T. J., Hunt, P. W., Laird, G. M., Pillai, S. K., Deeks, S. G., & Peluso, M. J. (2025). Galectin 9 Levels as a Potential Predictor of Intact HIV Reservoir Decay. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiae426
Vancouver
Serrano-Villar S, Gala A, Bacchetti P, Hoh R, di Germanio C, Cohn LB, et al. Galectin 9 Levels as a Potential Predictor of Intact HIV Reservoir Decay. The Journal of Infectious Diseases. 2025. doi:10.1093/infdis/jiae426
BibTeX
@article{SerranoVillar2025,
author = {Serrano-Villar, Sergio and Gala, Akshay and Bacchetti, Peter and Hoh, Rebecca and di Germanio, Clara and Cohn, Lillian B and Henrich, Timothy J and Hunt, Peter W and Laird, Gregory M and Pillai, Satish K and Deeks, Steven G and Peluso, Michael J},
title = {Galectin 9 Levels as a Potential Predictor of Intact HIV Reservoir Decay},
journal = {The Journal of Infectious Diseases},
year = {2025},
doi = {10.1093/infdis/jiae426}
}
EUVIMED